Cargando…
Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients
The widespread coronavirus SARS-CoV-2 has already infected over 4 million people worldwide, with a death toll over 280,000. Current treatment of COVID-19 patients relies mainly on antiviral drugs lopinavir/ritonavir, arbidol, and remdesivir, the anti-malarial drugs hydroxychloroquine and chloroquine...
Autores principales: | Liu, Tianxiao, Luo, Songyuan, Libby, Peter, Shi, Guo-Ping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255230/ https://www.ncbi.nlm.nih.gov/pubmed/32470470 http://dx.doi.org/10.1016/j.pharmthera.2020.107587 |
Ejemplares similares
-
Simultaneous Treatment of COVID-19 With Serine Protease Inhibitor Camostat and/or Cathepsin L Inhibitor?
por: Bittmann, Stefan, et al.
Publicado: (2020) -
Rational design of thioamide peptides as selective inhibitors of cysteine protease cathepsin L
por: Phan, Hoang Anh T., et al.
Publicado: (2021) -
Upregulation of Cathepsin X in Glioblastoma: Interplay with γ-Enolase and the Effects of Selective Cathepsin X Inhibitors
por: Majc, Bernarda, et al.
Publicado: (2022) -
Effective DNA Inhibitors of Cathepsin G by In Vitro Selection
por: Gatto, Barbara, et al.
Publicado: (2008) -
COVID-19, the Pandemic of the Century and Its Impact on Cardiovascular Diseases
por: Zhang, Yuanyuan, et al.
Publicado: (2021)